Sage wins historic FDA nod for postpartum depression therapy

Sage Therapeutics (NSDQ:SAGE) this week won FDA approval for the first medicine indicated to treat postpartum depression.
The Cambridge, Mass.-based company’s injection therapy, Zulresso, is slated to be available in late June.
Postpartum depression is the most common medical complication of childbirth, according to Sage, and affects roughly one in nine women who have given birth in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post Sage wins historic FDA nod for postpartum depression therapy appeared first on MassDevice.

Source: Mass Device - March 20, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Wall Street Beat sagetherapeutics Source Type: news